Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene

Maturitas

Volumn 59, Issue 1, 2008, Pages 62-71

  Lambrinoudaki, Irene V ^a   Christodoulakos, George E ^a   Economou, Emmanuel V ^a   Vlachou, Sofia A ^a   Panoulis, Constantinos P ^a   Alexandrou, Andreas P ^a   Kouskouni, Evangelia E ^a   Creatsas, George C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis; Estrogen; Ghrelin; Hormone therapy; Leptin; Postmenopausal; Raloxifene; Tibolone

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL PLUS NORETHISTERONE ACETATE; FAS ANTIGEN; FAS LIGAND; FOLLITROPIN; GHRELIN; INTERLEUKIN 1BETA CONVERTING ENZYME; LEPTIN; RALOXIFENE; TIBOLONE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HEART PROTECTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NORMAL HUMAN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BODY MASS INDEX; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; ESTROGENS, CONJUGATED (USP); FAS LIGAND PROTEIN; FEMALE; FOLLICLE STIMULATING HORMONE; GHRELIN; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN; LEPTIN; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; RALOXIFENE; SEX HORMONE-BINDING GLOBULIN;

EQUIDAE;

EID: 38949148961     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.10.003     Document Type: Article

References (78)

1. Wagner J.D., Kaplan J.R., and Burkman R.T. Reproductive hormones and cardiovascular disease mechanism of action and clinical implications. Obstet Gynecol Clin North Am 29 (2002) 475-493
2. Alexander J., and Clearfield M. Cardiovascular disease after menopause: a growing epidemic. Minerva Ginecol 58 (2006) 35-40
3. Grodstein F., Manson J.E., and Stampfer M.J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Ann Intern Med 135 (2001) 1-8
4. The Writing Group for The Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
5. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
6. Koh K.K., and Yoon B.K. Controversies regarding hormone therapy: Insights from inflammation and hemostasis. Cardiovasc Res 70 (2006) 22-30
7. Francucci C.M., Romagni P., and Boscaro M. Raloxifene: bone and cardiovascular effects. J Endocrinol Invest 28 (2005) 85-89
8. Van Harmelen V., Reynisdottir S., Eriksson P., et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 47 (1998) 913-917
9. Ahima R.S. Central actions of adipocyte hormones. Trends Endocrinol Metab 16 (2005) 307-313
10. Sierra-Honigmann M.R., Nath A.K., Murakami C., et al. Biological action of leptin as an angiogenic factor. Science 281 (1998) 1683-1686
11. Oda A., Taniguchi T., and Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci 47 (2001) 141-150
12. Beltowski J. Leptin and atherosclerosis. Atherosclerosis 189 (2006) 47-60
13. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
14. Di Carlo C., Tommaselli G.A., and Nappi C. Effects of sex steroid hormones and menopause on serum leptin concentrations. Gynecol Endocrinol 16 (2002) 479-491
15. Baranowska B., Radzikowska M., Wasilewska-Dziubinska E., Roguski K., and Polonowski A. Relationship among leptin, neuropeptide Y, and galanin in young women and in postmenopausal women. Menopause 7 (2000) 149-155
16. Haffner S.M., Mykkanen L., and Stern M.P. Leptin concentrations in women in the San Antonio Heart Study: effect of menopausal status and postmenopausal hormone replacement therapy. Am J Epidemiol 146 (1997) 581-585
17. Rosenbaum M., Nicolson M., Hirsch J., et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol 81 (1996) 3424-3427
18. Nakazato M., Murakami N., Date Y., et al. A role for ghrelin in the central regulation of feeding. Nature 409 (2001) 194-198
19. Papotti M., Ghe C., Cassoni P., et al. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab 85 (2000) 3803-3807
20. Garcia E.A., and Korbonits M. Ghrelin and cardiovascular health. Curr Opin Pharmacol 6 (2006) 142-147
21. Matsubara M., Sakata I., Wada R., Yamazaki M., Inoue K., and Sakai T. Estrogen modulates ghrelin expression in the female rat stomach. Peptides 25 (2004) 289-297
22. Kellokoski E., Poykko S.M., Karjalainen A.H., et al. Estrogen replacement therapy increases plasma ghrelin levels. J Clin Endocrinol Metab 90 (2005) 2954-2963
23. Chu M.C., Cosper P., Nakhuda G.S., and Lobo R.A. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome. Fertil Steril 86 (2006) 1669-1675
24. Seli E., Guzeloglu-Kayisli O., Cakmak H., Kayisli U.A., Selam B., and Arici A. Estradiol increases apoptosis in human coronary artery endothelial cells by up-regulating fas and fas ligand expression. J Clin Endocrinol Metab 91 (2006) 4995-5001
25. Troyanov S., Hebert M.J., Masse M., Vigneault N., Sirois I., and Madore F. Soluble Fas: a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 41 (2003) 1043-1051
26. Christodoulakos G.E., Lambrinoudaki I.V., Economou E.V., et al. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. Atherosclerosis 193 (2007) 142-150
27. Parhami F., Tintut Y., Ballard A., Fogelman A.M., and Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Cir Res 88 (2001) 954-960
28. Bouloumie A., Marumo T., Lafontan M., et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 13 (1999) 1231-1238
29. Elbatarny H.S., and Maurice D.H. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signalling complex. Am J Physiol Endocrinol Metab 289 (2005) 695-702
30. Shamsuzzaman A.S., Winnicki M., Wolk R., et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109 (2004) 2181-2185
31. van Dielen F.M., van't Veer C., Schols A.M., Soeters P.B., Buurman W.A., and Greve J.W. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 25 (2001) 1759-1766
32. Schiekofer S., Galasso G., Sato K., Kraus B.J., and Walsh K. Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. Arterioscler Thromb Vasc Biol 25 (2005) 1603-1609
33. Park H.Y., Kwon H.M., Lim H.J., et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33 (2001) 95-102
34. Artwohl M., Roden M., Holzenbein T., Freudenthaler A., Waldhausl W., and Baumgartner-Parzer S.M. Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord 26 (2002) 577-580
35. Qamar A., Sheikh S.Z., Masud A., et al. In vitro and in vivo protection of stellate cells from apoptosis by leptin. Dig Dis Sci 51 (2006) 1697-1705
36. Papathanassoglou E., El-Haschimi K., Li X.C., Matarese G., Strom T., and Mantzoros C. Leptin receptor expression and signaling in lymphocytes: kinetics during lymphocyte activation, role in lymphocyte survival, and response to high fat diet in mice. J Immunol 176 (2006) 7745-7752
37. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57 (1994) 129-144
38. Hebert M.J., Masse M., Vigneault N., Sirois I., Troyanov S., and Madore F. Soluble Fas is a marker of coronary artery disease in patients with end-stage renal disease. Am J Kidney Dis 38 (2001) 1271-1276
39. Blanco-Colio L.M., Martin-Ventura J.L., de Teresa E., et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST. Arterioscler Thromb Vasc Biol 27 (2007) 168-174
40. Pohelman E.T., Toth M.J., and Gardner A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 123 (1995) 673-675
41. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 20 (1991) 47-63
42. Thomas T., Burguera B., Melton III L.J., et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 49 (2000) 1278-1284
43. Tchernof A., Poehlman E.T., and Després J.P. Body fat distribution, the menopause transition, and hormone replacement therapy. Diab Metab 26 (2000) 12-20
44. Lambrinoudaki I.V., Christodoulakos G.E., Panoulis C.P., et al. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women. Maturitas 48 (2004) 107-113
45. Hadji P., Gorke K., Hars O., Bauer T., Emons G., and Schulz K.D. The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women. Maturitas 37 (2000) 105-111
46. Lavoie H., Taylor A., Sharpless J., Anderson E., Strauss C., and Hall J. Effects of short-term hormone replacement on serum leptin levels in postmenopausal women. Clin Endocrinol 5 (1999) 415-422
47. Elbers J.M., de Roo G.W., Popp-Snijders C., et al. Effects of administration of 17beta-oestradiol on serum leptin levels in healthy postmenopausal women. Clin Endocrinol 51 (1999) 449-454
48. Konukoglu D., Serin O., and Ercan M. Plasma leptin levels in obese and non-obese postmenopausal women before and after hormone replacement therapy. Maturitas 36 (2000) 203-207
49. Di Carlo C., Tommaselli G.A., Pisano G., et al. Serum leptin levels in postmenopausal women: effects of transdermal hormone replacement therapy. Menopause 7 (2000) 36-41
50. Di Carlo C., Tommaselli G.A., Sammartino A., Bifulco G., Nasti A., and Nappi C. Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 11 (2004) 466-473
51. Lambrinoudaki I., Christodoulakos G., Panoulis C., et al. Determinants of serum leptin levels in healthy postmenopausal women. J Endocrinol Invest 26 (2003) 1225-1230
52. Basurto L., Galvan R., Ochoa R., Fonseca E., and Zarate A. Circulating leptin doesn not change in postmenopausal women receiving replacement therapy with tibolone. Ginecol Obstet Mex 68 (2000) 416-419
53. Gol M., Ozsener S., Sendag F., et al. Does tibolone affect serum leptin levels and body weight in postmenopausal women?. Arch Gynecol Obstet 272 (2005) 127-130
54. Panidis D.K., Rousso D.H., Kourtis A.I., Stergiopoulos K.N., Mavromatidis G.A., and Katsikis I.K. The influence of tibolone upon serum leptin levels in post-menopausal women. Eur J Obstet Gynecol Reprod Biol 96 (2001) 85-87
55. Cakmak A., Posaci C., Dogan E., Caliskan S., Guclu S., and Altunyurt S. Raloxifene increases serum leptin levels in postmenopausal women: a prospective study. Am J Obstet Gynecol 193 (2005) 347-351
56. Tommaselli G.A., Di Carlo C., Di Spiezio Sardo A., et al. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene. Menopause 13 (2006) 660-668
57. Nagaya N., Kojima M., Uematsu M., et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280 (2001) 1483-1487
58. Okumura H., Nagaya N., Enomoto M., Nakagawa E., Oya H., and Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol 39 (2002) 779-783
59. Katugampola S.D., Pallikaros Z., and Davenport A.P. [125I-His(9)]-ghrelin, a novel radioligand for localizing GHS orphan receptors in human and rat tissue: up-regulation of receptors with athersclerosis. Br J Pharmacol 134 (2001) 143-149
60. Wiley K.E., and Davenport A.P. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 136 (2002) 1146-1152
61. Li W.G., Gavrila D., Liu X., et al. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109 (2004) 2216-2221
62. Suematsu M., Katsuki A., Sumida Y., et al. Decreased circulating levels of active ghrelin are associated with increased oxidative stress in obese subjects. Eur J Endocrinol 153 (2005) 403-407
63. Tesauro M., Schinzari F., Iantorno M., et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112 (2005) 2986-2992
64. Kotani K., Sakane N., Saiga K., et al. Serum ghrelin and carotid atherosclerosis in older Japanese people with metabolic syndrome. Arch Med Res 37 (2006) 903-906
65. Hansen T.K., Dall R., Hosoda H., et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) 56 (2002) 203-206
66. Cummings D.E., Weigle D.S., Frayo R.S., et al. Human plasma ghrelin levels after diet-induced weight loss and gastric bypass surgery. N Engl J Med 346 (2002) 1623-1630
67. Tschop M., Weyer C., Tataranni P.A., Devanarayan V., Ravussin E., and Heiman M.L. Circulating ghrelin levels are decreased in human obesity. Diabetes 50 (2001) 707-709
68. Shiiya T., Nakazato M., Mizuta M., et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87 (2002) 240-244
69. Pagotto U., Gambineri A., Vicennati V., Heiman M.L., Tschöp M., and Pasquali R. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab 87 (2002) 5625-5629
70. Gambineri A., Pagotto U., Tschöp M., et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. J Endocrinol Invest 26 (2003) 629-634
71. Purnell J.Q., Weigle D.S., Breen P., and Cummings D.E. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 88 (2003) 5747-5752
72. Veldhuis J.D., Keenan D.M., Iranmanesh A., Mielke K., Miles J.M., and Bowers C.Y. Estradiol potentiates ghrelin-stimulated pulsatile growth hormone secretion in postmenopausal women. J Clin Endocrinol Metab 91 (2006) 3559-3565
73. Barrett-Connor E., Grady D., Sashegyi A., et al. MORE investigators (multiple outcomes of raloxifene evaluation). Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE trial. J Am Med Assoc 287 (2002) 847-857
74. Saitta A., Altavilla D., Cucinotta D., et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 21 (2001) 1512-1519
75. Christodoulakos G., Lambrinoudaki I., Panoulis C., Rizos D., Coutoukos J., and Creatsas G. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. Fertil Steril 79 (2003) 455-456
76. Colacurci N., Manzella D., Fornaro F., Carbonella M., and Paolisso G. Endothelial function and menopause, effects of raloxifene administration. J Clin Endocrinol Metab 88 (2003) 2135-2140
77. Christodoulakos G., Lambrinoudaki I., Panoulis C., Papadias C., Economou E., and Creatsas G. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. Fertil Steril 82 (2004) 634-638
78. Barrett-Connor E., Mosca L., Collins P., et al. Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 (2006) 125-137